FLT3-MUTATED ACUTE MYELOID LEUKEMIA OUTCOMES IN A NORTHEAST BRAZILIAN UNIVERSITY HOSPITAL
DOI:
https://doi.org/10.46765/2675-374X.2024v5n1p225Abstract
Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene occur in approximately 25-45% of new diagnoses of Acute myeloid leukemia. The addition of FLT3 inhibitors to conventional protocols improves overall survival in this condition. Objectives: To assess the incidence of FLT3 gene mutation among patients diagnosed with AML at Walter Cantídio University Hospital; Describe access to FLT3 inhibitors and bone marrow transplantation (BMT), and the overall survival of this group. Methodology: Retrospective evaluation of medical records of patients treated for AML between 2020 and 2022. Statistical analysis was performed using the Kaplan-Meier method to estimate survival probability. Results: 47 patients were diagnosed with AML during this period, of whom 17% had FLT3+ mutation. 3/8 patients accessed FLT3 inhibitors. The median survival with FLT3+ mutation was 9.1 months vs. 12.9 months in FLT3- (p = 0.196). The overall survival of AML patients was 30.9% at 2 years. 11/47 patients underwent allogeneic BMT. Conclusion: The addition of targeted therapies and BMT may contribute to reduce mortality in AML. Elderly patients and those not undergoing HSCT have worse outcomes.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
This work is licensed under a Creative Commons Attribution 4.0 International License.
License and Copyright Policy
The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.
-
License
- All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
- This license permits anyone to:
- Share: Copy and redistribute the material in any medium or format.
- Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
- The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.
More information about the license can be found here: Creative Commons Attribution 4.0 International License.
-
Authors’ Rights
- Authors retain the copyright to their work.
- Authors grant JBMTCT the right to publish the work and make it openly accessible online.
- Authors are free to:
- Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
- Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.
-
No Embargo
- There is no embargo period; articles are made freely available immediately upon publication.
-
Ethical Use
- Users of JBMTCT articles must ensure proper citation of the authors and the journal.
- Articles must not be used in ways that violate ethical or legal standards.
-
Disclaimer
- While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.
For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br
JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.
